Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration

Inclusion Criteria:

• Treatment naïve juxtafoveal and/or SFNV secondary to Neovascular Age- RelatedMacular Degeneration (nAMD) with leakage involving the fovea in the study eye priorto Screening, or have a diagnosis of Neovascular Age- Related Macular Degeneration (nAMD) in study eye within 3 months prior to screening and received up to 2 monthlyinjections of 2 mg aflibercept with last injection approximately 4 weeks prior toScreening

• Have provided written consent

Exclusion Criteria:

• Monocular subject or Best Corrected Visual Acuity (BCVA) score of <20 ETDRS lettersor 20/400 in fellow eye at Screening

• Have evidence of a scar, fibrosis, or atrophy of >50% of the total lesion in thestudy eye.